Findings

What do systematic reviews say?

15 questions · 15 findings · 6 reviews · Haematology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 14 · 93.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 6.7%Moderate 0 · 0%High 0 · 0%

Summary of findings table ‐ Platelet transfusion vs no platelet transfusion

Quality of life (as defined by the individual studies) · thrombocytopenia

The review found no eligible studies for this question.

1 finding from 1 review

Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Quality of life · individuals with HL

The review found no eligible studies for this question.

1 finding from 1 review

Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo

Quality of life · individuals with moderate or severe COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Hyperimmune immunoglobulin for people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hyperimmune immunoglobulin from human plasma vs saline placebo

Quality of life · individuals with moderate or severe COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Hyperimmune immunoglobulin for people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Casirivimab/imdevimab vs placebo

Quality of life · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bamlanivimab vs placebo

Quality of life · non‐hospitalised individuals with COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bamlanivimab vs placebo

Quality of life · hospitalised individuals with COVID‐19 (moderate to severe disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Casirivimab/imdevimab vs usual care

Quality of life · hospitalised individuals with COVID‐19 (moderate to severe disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Convalescent plasma vs standard plasma

Quality of life, · individuals with moderate to severe disease

The review found no eligible studies for this question.

1 finding from 1 review

Convalescent plasma for people with COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

Quality of life, · individuals with moderate to severe disease

1 finding from 1 review

Convalescent plasma for people with COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 483 participants
Low

Bamlanivimab/etesevimab vs placebo

Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sotrovimab vs placebo

Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Regdanvimab vs placebo

Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Convalescent plasma vs human immunoglobulin

Quality of life ‐ not reported · individuals with moderate to severe disease

The review found no eligible studies for this question.

1 finding from 1 review

Convalescent plasma for people with COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vitamin D vs placebo or usual care

Quality of life, including fatigue and neurological functioning; · individuals with moderate to severe disease

The review found no eligible studies for this question.

1 finding from 1 review

Vitamin D supplementation for the treatment of COVID‐19: a living systematic review 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found